BioTrove System Enables Rapid Development of DNA Gene Methylation Biomarkers for Cancer Research
Woburn, MA, July 10, 2007 - BioTrove, Inc. today announced an agreement with OncoMethylome Sciences (Euronext: ONCO) for supply and use of BioTrove's OpenArray™ PCR screening technology in the development of DNA gene methylation cancer biomarkers.
"We look forward to enhancing our pharmacogenomic services with the BioTrove OpenArray system, which enables us to test our many proprietary methylation markers on clinical samples in a fast, high-throughput manner," said Wim Van Criekinge, Vice President, Biomarker and Pharmacogenomics Research, OncoMethylome.
Under the terms of the multi-year agreement, BioTrove will supply OncoMethylome with OpenArray nanoplates and instrumentation for use in research and development of DNA methylation-based biomarkers. Financial terms were not disclosed.
Gene methylation, a control mechanism that regulates gene expression in DNA, has become an important area of cancer diagnostics research. OncoMethylome products are designed to detect cancer cells and predict their response to cancer therapy by identifying specific methylation markers in patient DNA samples through PCR.
"Our supply agreement with OncoMethylome confirms the value of OpenArray technology in accelerating the development of diagnostic biomarkers - an important research area impacting patient health and treatment," said Al Luderer, Ph.D., president and CEO, BioTrove. "Our company mission is to advance life science research through our technology, and we are especially pleased OncoMethylome has adopted our system for this purpose."
About BioTrove, Inc.
BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world's ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove's products and services ensure that an industry committed to accuracy and speed can meet business goals.
RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.
The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.
For more information, please visit www.biotrove.com or contact:
Dr. Albert Luderer, President and CEO
BioTrove, Inc.
781-721-3648
info@biotrove.com
Arielle Bernstein
Makovsky + Company
212-508-9643
abernstein@makovsky.com
|
